Technology transfer into Europe
Bring your formulation, methods and process knowledge. We assess what can transfer, what needs further work and how the receiving site would be qualified.
EUROPEAN NEARSHORING · ATHENS, GREECE
Complex molecules.
A clearer route into Europe.
Nearshoring for Complex Molecules or Biotechnological Startups. Connect formulation development, technology transfer and manufacturing planning with a partner in Greece.
Our starting point is your drug product: non-sterile dosage forms, analytical readiness and a programme defined around your molecule.
Turn a manufacturing question into a development plan
Whether you are relocating an existing programme, building your first drug product or exploring a second European source, start with a technical conversation. We bring R&D and manufacturing into the same discussion, so the next decision is grounded in your product.
Development for biotech startups
Define the dosage form, analytical needs and development sequence before committing to a manufacturing programme. Agree staged work packages around the evidence you already have.
A potential second source
Discuss supply continuity through an additional European manufacturing route. Site fit, transfer data, validation and regulatory responsibilities are evaluated before supply is agreed.
PROGRAMME EXPLORER
Where does your programme start?
Choose your objective and continue with a focused enquiry.
FOR THE FIRST TECHNICAL DISCUSSION
Transfer to Europe
Existing formulation · analytical methods · process data · target market
Continue with this objective →The formulation challenge shapes the platform
Complexity can sit in solubility, stability, moisture sensitivity, oxygen exposure or process transfer. We start by understanding that challenge and assessing whether our available platform can address it.
Formulation & analytics
Discuss formulation or reformulation, analytical development, stability planning and pilot work. Deliverables are defined against your product and target market.
Environmental control
A low-humidity room below 10% RH and nitrogen capability on selected liquid lines support the evaluation of moisture- or oxygen-sensitive formulations. Suitability is established per process.
Connected manufacturing
Oral liquids, semisolids, capsules, tablets and powders across a connected development and manufacturing model in Athens. The selected dosage form and site must fit the authorised scope.
A precise fit for your molecule
Our nearshoring offer centres on non-sterile drug-product development and manufacturing. For complex molecules, feasibility depends on the material, dosage form, potency and containment requirements, analytical methods and stability profile.
A biotechnology startup does not necessarily need biologics manufacturing. If your programme requires biological drug-substance production, cell culture or fermentation, cell or gene therapies, sterile processing or aseptic fill-finish, raise this at the outset: these are not presented here as established Sikalias capabilities. We first determine whether there is a suitable role within our documented scope.
Review scope and quality documentation →What a European base can mean for your team
One technical conversation
Discuss development and manufacturing together with the Sikalias team, with site selection and QA involvement tied to the project.
A plan you can evaluate
Define work packages, data needs, decision points and commercial assumptions before agreeing the programme. Timing and batch scale follow the assessment.
Clear responsibilities
Agree confidentiality, IP and dossier rights, material responsibilities, regulatory roles and the quality agreement. Exchange confidential information through an agreed channel.
Questions before a nearshoring discussion
Can you take over an existing formulation?
We can assess a technology-transfer programme. Share the dosage form, dossier status, methods, current manufacturing location, expected volumes and target markets. A proposal follows the assessment of the technical and authorisation fit.
Can an early-stage biotechnology company approach you?
Yes. A non-confidential outline is enough to begin. Explain the molecule class, intended dosage form and development stage. We will discuss the available evidence and the work needed to define a suitable drug-product programme.
Do you offer a fixed minimum batch size or transfer timeline?
These depend on the product, equipment fit, process, analytical readiness and validation needs. We agree them for the specific programme rather than publish a universal commitment.
What should I send first?
The molecule or product class, dosage form, development stage, target market, approximate scale and the main transfer or formulation challenge. Please do not submit patient data or confidential dossiers through the initial enquiry form.
Bring the challenge. Let’s define the next step.
Share a short, non-confidential outline. We can then discuss product fit, technical priorities and the route to a scoped development or transfer programme.
Discuss my nearshoring project →